Minimal change XXXX associated with non-hodgkin lymphoid disorders: a retrospective study of 18 cases.

@entity1 @entity230 @entity1893 @entity8 @entity1071 @entity3191 @entity1072 @entity1582 @entity134 @entity1892 @entity74 @entity1073 @entity810 @entity1985 @entity8057
Few studies have examined the occurrence of minimal change @entity1985 (MCNS) in @entity1 with @entity1893 ( @entity1893 ). We report here a series of 18 @entity1 with MCNS occurring among 13,992 new cases of @entity1893 . We analyzed the clinical and pathologic characteristics of this association, along with the response of @entity1 to treatment, to determine if this association relies on a @entity74 . The most frequent NHLs associated with MCNS were Waldenstr  m @entity8057 (33.3%), marginal zone @entity1892 (27.8%), and @entity1072 (22.2%). Other @entity1071 included @entity1582 , @entity1073 , and @entity3191 . In 4 @entity1 MCNS occurred before @entity1893 (mean delay, 15 mo), in 10 @entity1 the disorders occurred simultaneously, and in 4 @entity1 MCNS was diagnosed after @entity1893 (mean delay, 25 mo). Circulating monoclonal immunoglobulins were present in 11 @entity1 . A nontumoral interstitial infiltrate was present in renal biopsy specimens from 3 @entity1 without significant @entity8 . @entity810 resulting from @entity8 or renal hypoperfusion was present in 6 @entity1 . MCNS relapse occurred more frequently in @entity1 treated exclusively by @entity134 therapy (77.8%) than in those receiving @entity230 associated with chemotherapy (25%). In conclusion, MCNS occurs preferentially in @entity1893 originating from B cells and requires an aggressive therapeutic approach to reduce the risk of MCNS relapse.
